Acetylon Pharmaceuticals Inc.

There are a number of histone deacetylase inhibitors on the market and in development that regulate gene expression in normal as well as cancer cells but can lead to a number of serious side effects. Acetylon Pharmaceuticals Inc. is developing small-molecule compounds that selectively inhibit HD AC for the treatment of cancers as well as inflammatory neurodegenerative, genetic and infectious disease.